Oct 24, 2023 · HLX43 showed promising efficacy and safety results in our preclinical evaluation. This innovative novel PD-L1-targeting ADC has the potential to become a new treatment …

Sep 21, 2023 · HK) announced that the latest results of two ADC (Antibody-drug Conjugate) products, HLX42, the novel EGFR-targeting ADC, and HLX43, the PD-L1 targeting ADC, will …

HLX43 exhibited superior anticancer efficacy compared to anti-PD-L1-GGFG-Dxd at equal doses in all models tested, including those with low PD-L1 levels, high heterogeneity, and non …

HLX43 is a novel PD-L1-targeting ADC consisting of an engineered anti-PD-L1 humanised IgG1 antibody linked to a camptothecin-based toxin, with a drug to antibody ratio of 8.

Oct 25, 2023 · HK) announced that the results from the preclinical study of HLX43, the novel PD-L1- targeting ADC which was developed by the company based on the collaboration with …

Nov 24, 2023 · Several non-clinical studies have shown that HLX43 has good anti-tumour effects and favourable safety profiles and potent tumour suppression in several CDX and PDX models …

HLX43 is a PD-L1-targeting ADC, composed of an engineered version of the anti-PD-L1 humanized IgG1 antibody(HLX20), conjugated via our next- generation linker to a …

HLX43 showed promising efficacy and tolerability in preclinical assessments. It may offer a novel treatment for PD-1/PD-L1 inhibitor R/R cancers like NSCLC, HNSCC, ESCC, MEL, and OVC.

Oct 25, 2023 · HLX43 showed promising efficacy and safety results in our preclinical evaluation. This innovative novel PD-L1-targeting ADC has the potential to become a new treatment …

Nov 27, 2023 · Several non-clinical studies have shown that HLX43 has good anti-tumour effects and favourable safety profiles and potent tumour suppression in several CDX and PDX models …